FDA Hosts Workshop to Improve Community Access to Life-Saving Epinephrine
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a workshop on December 16, 2025, to talk about making epinephrine easier to get for people who might have severe allergic reactions (anaphylaxis). This effort aims to save lives by getting epinephrine into more hands, especially in community places. Everyone can join online or in person and share their thoughts by January 16, 2026, helping shape future access and safety improvements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Many at-risk patients lack or avoid epinephrine
Anaphylaxis can progress within 15 to 30 minutes and epinephrine is the only effective first-line treatment. The document says up to 5 percent lifetime prevalence in the U.S. and about 200 deaths annually, and it notes patients prescribed epinephrine may not have it available during an event or may choose not to use it because of knowledge gaps, fear, stigma, or incorrect use.
Community sites often lack epinephrine policies
Schools, workplaces, restaurants, sports facilities, transportation vehicles, and public venues may lack policies for epinephrine storage, staff training, and emergency administration. That institutional lack of preparedness can reduce access to epinephrine where anaphylaxis commonly happens.
State liability rules discourage stocking epinephrine
State laws vary regarding Good Samaritan protections for lay administration of epinephrine, and these liability concerns can discourage institutions from maintaining emergency epinephrine supplies.
Cost of epinephrine limits community availability
The document identifies economic obstacles from the cost of epinephrine products as a barrier to having community‑use epinephrine available in public settings, which can limit access during emergencies.
Rural disparities reduce timely epinephrine access
The document notes geographic disparities, especially in rural communities where pharmacies may be spread out and emergency medical services can have longer response times, which can limit timely access to epinephrine.
Prescription and provider authorization create access hurdles
The notice identifies procedural barriers such as obtaining healthcare provider authorization and maintaining a current prescription for epinephrine as factors that can limit access to this life‑saving medication.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in